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Abstract
Background: There are limited data supporting the effectiveness of buprenorphine treatment for opioid use disorder among ado-
lescents.
Objectives: The aim of this study was to investigate the outcomes of using buprenorphine for inpatient medically assisted with-
drawal of vulnerable adolescents with opioid use disorder.
Methods: Twelve consecutive vulnerable adolescents due to working or living in streets were admitted to the Child and Adolescent
Psychiatric Ward of Ali Ibn-e-Abi Talib Hospital for treatment of opioid use disorder using buprenorphine-assisted withdrawal. The
clinical chart abstraction of patients’ files was made to provide the baseline situation of the patients, as well as treatment progress
at discharge and one and three months post-discharge.
Results: All the complaints of pain and other withdrawal signs and symptoms decreased dramatically within the first four days of
treatment. At one-month follow-up, all study participants were still in the foster care and the urine tests for morphine and metham-
phetamine were negative. At the three-month follow-up, the older sister of the only one 15-year-old adolescent took the responsibility
of his guardianship. The urine tests of all study participants were negative in month 3.
Conclusions: Medically managed opioid withdrawal must be considered only as a part of a comprehensive psychosocial program
providing a stable living environment, adolescent welfare, and custody services. The treatment program also proved its safety and
effectiveness for the management of pain and other opioid withdrawal signs and symptoms among adolescents.
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1. Background
A growing concern regarding illicit drug use among
vulnerable youth has emerged in Iran. National Mental
Health Survey data showed that the prevalence of opioid
dependence among the 15 to 19-year-old population was
0.96% in 2011 (1). Another household survey in 2011 re-
ported that 13.6% of all 1.325 million drug addicts were 15 to
19-years-old (2). Opium is the most common opioid of use,
followed by heroin, crack heroin, and prescription opioids
(1, 2). Crack is the street name for a form of the illegal drug
in the Iran drug market that its main ingredient is heroin
(3). In a national survey among students of 6 to 12th grades
in 10 provinces of the country, the prevalence of the life-
time, last year, and last month opium use was 2.5%, 1.5%, and
0.9%, respectively (4).
Vulnerable children, who live or work in streets, are ex-
pected to be particularly at risk of drug use disorders. The
prevalence of current opioid use is reported in the range
of 1.3% to 9% among street children in Iran (5-8). A meta-
analysis study showed a high unemployment rate, low so-
cioeconomic status, and illiteracy among parents of street
children in Iran. It also indicated that most street children
were in contact with their families and came to the streets
for work, which suggested the contribution of the low so-
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cioeconomic status of the parents to children’s labor in
the streets. The weighted prevalence of addiction history
among a family member, father, and mother of street chil-
dren was 56%, 44%, and 23%, respectively (9).
The high prevalence of opioid use among street chil-
dren necessitates the provision of standard treatment ser-
vices by specialized drug treatment services within a com-
prehensive psychosocial support program coordinated by
foster care system of the State Welfare Organization (SWO)
(10).
There are limited data on safety and effectiveness of
opioids agonist medications for treatment of opioids use
disorder among children and adolescents (11-13). A few in-
ternational studies provided data on medication-assisted
opioid withdrawal (14-16) and opioid maintenance treat-
ment (16-19) of opioids use disorder among adolescents
and youths.
Buprenorphine is safe and effective both in supervised
withdrawal and in the maintenance treatment of adult
people with opioid use disorder (20). It has been intro-
duced to the network of drug treatment clinics in Iran for
the treatment of opioid use disorder since 2006 (21). It is
a µ-opioid partial agonist with a safer side effect profile
and less severe withdrawal as compared to full opioid ag-
onists (22), which makes it a potential candidate for the
treatment of opioids among adolescents (16).
2. Objectives
The aim of this study was to explore the feasibility and
effectiveness of inpatient buprenorphine-assisted with-
drawal of vulnerable adolescents with opioid use disorder
who were referred to the child and adolescent psychiatric
ward of Ali Ibn-e-Abi Talib Treatment and Research Center
of Zahedan University of Medical Sciences (ZAUMS) in Za-
hedan, Iran.
3. Patients and Methods
This open-label observational study evaluated the fea-
sibility and effectiveness of buprenorphine-assisted with-
drawal for opioid use disorder among vulnerable adoles-
cents due to living or working in streets, who were admit-
ted to a child and adolescent psychiatric ward.
3.1. Setting
The treatment was delivered at the child and adoles-
cent psychiatric ward of Ali Ibn-e-Abi Talib academic gen-
eral hospital affiliated to Zahedan University of Medical
Sciences (ZAUMS), the center of Sistan and Baluchistan
province in the southeast of Iran, which provides inpatient
and outpatient treatment services under the direct super-
vision of a child and adolescent psychiatrist. The child and
adolescent psychiatric ward staff and equipment were de-
scribed elsewhere (23).
3.2. Patients
The inclusion criteria were an age of 12 to 17 years, a
diagnosis of moderate-to-severe opioid use disorder based
on DSM-5, admission to the child and adolescent psychi-
atric ward, the ability to understand and willingness to
provide written assent, and provision of informed consent
by parents or legal guardians. The exclusion criteria in-
clude having pervasive developmental disorders.
3.3. Intervention
The treatment intervention was part of a program for
the management of vulnerable children and adolescents
in Zahedan city, in which children and adolescents caught
by the police because of living or working in the street were
transferred to foster care services since their parents were
not competent for guardianship mainly due to active sub-
stance use and/or unstable housing.
The vulnerable children and adolescents, who were in
need of opioid withdrawal treatment identified by foster
care staff, were referred to the hospital with a court or-
der mentioning that they were on the attorney general
guardianship and granting consent for necessary treat-
ment interventions. The procedures of buprenorphine-
assisted withdrawal were explained to the study partici-
pants and their informed assent was obtained. The study
was approved by the Ethics Committee of ZAUMS.
In this study, we integrated buprenorphine-assisted
opioid withdrawal management within the child and
adolescent psychiatric sub-specialty services for adoles-
cents with opioid use disorder. Before that, available
services for opioids treatment were limited to the symp-
tomatic management of opioid withdrawal with cloni-
dine, NSAIDs (nonsteroidal anti-inflammatory drugs), and
antihistamines, as well as treatment of psychiatric comor-
bidities (23). We used a flexible dose reduction schedule of
buprenorphine-assisted withdrawal regimen (buprenor-
phine mono-product, 2 mg sublingual tablets manufac-
tured by Faran Shimi Pharmaceutical Co.) from previous
studies (16, 24) and trained psychiatric residents for its im-
plementation. Nurses were trained for supervised dosing
of buprenorphine in the ward. The clinical psychologist of
the ward was also trained to provide needed information
regarding rationale, benefits, process, and potential side
effects of buprenorphine treatment during an informed
assent process to participants. The proper implementa-
tion of the treatment plan was supervised by a child and
adolescent psychiatrist.
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Eligible adolescents, who had a current physiologic de-
pendence to opioids, entered the study. After admission to
the ward, a thorough assessment was conducted by psy-
chiatric residents. Patients needed to abstain from opi-
oids at least for six hours for short-acting opioids such as
heroin and crack heroin and 8 - 10 hours for long-acting
opioids such as opium and opium residues. The first
dose of buprenorphine (2 mg) was dispensed by nurses
when the patient showed mild-to-moderate withdrawal (>
5 in COWS) measured by the Clinical Opioid Withdrawal
Scale (COWS). Since the study participants had been re-
ferred from the foster home, there was adequate time
passed from their last opioid use and during their first
assessment, all of them had moderate to severe with-
drawal scores and reported mild to severe pain. The
nurses trained patients to hold buprenorphine tablets un-
der their tongues until it dissolved completely. All phar-
macotherapies including buprenorphine doses were dis-
pensed under the direct supervision of the nurses. After
the first dose of buprenorphine, patients were observed
every two hours and other doses of 2 mg buprenorphine
(up to 8 mg) were administered if needed. On day 2, pa-
tients received the total daily dose of day 1 in the morning.
During days 2 and 3, the buprenorphine dose increased to
2 - 4 mg (up to 12 mg) if patients had mild to moderate
withdrawal. From day 4, a flexible dose reduction regimen
(25% dose reduction every 2 - 3 days) was administered and
the buprenorphine dose was tapered and discontinued.
The rate of buprenorphine dose reduction was tailored to
avoid precipitating withdrawal signs and symptoms. Pa-
tients received one buprenorphine dose as their last dose.
They tolerated the discontinuation of buprenorphine dose
with no need to receive symptomatic medications. All pa-
tients also received twice-weekly counseling sessions pro-
viding psychoeducation, motivational interviewing, and
relapse prevention techniques.
Data were extracted from the patients’ files and an-
alyzed by the statistical package for the social sciences
(SPSS), version 20. The treatment staff followed the clini-
cal situation of patients at one and three months after dis-
charge. The study protocol, assessments, and assent pro-
cess were approved by ZAUMS Ethics Committee.
4. Results
12 adolescents (8 boys and 4 girls) with moderate to se-
vere opioid use disorder were consecutively admitted to
the treatment setting, from November 2015 to March 2016.
Their age range was 12 to 17 years (mean± SD: 13.66± 1.55).
All of the patients were single and did not admit any pre-
vious history of sexual activities except two girls (16.6%).
Among female patients, no one was pregnant. Regarding
educational status, two of them were illiterate and the rest
had completed up to seven years of education (average
completed years of education: 2.75± 2.37). However, at the
time of the study, none of them was going to school. Three
of the cases did not have any history of education. In terms
of their employment status, 6 (50%) of them reported to be
vendors, 3 of them reported to be a beggar, and only one of
them (8.3%) was a salesman in a store whereas the rest did
not report any history of work.
The mothers of all study participants were alive while
the fathers of three (33.3%) were deceased. Only the parents
of four participants were living together and the parents of
the rest were divorced or separated. All adolescents, except
one, reported stable housing. The parents of the majority
of cases were illiterate. All fathers and 10 (83.3%) mothers
suffered from current substance use disorder. According
to the court report, none of the families had parenting eli-
gibility because of active drug use of at least one parent (all
cases), as well as involvement in drug-related illegal activ-
ities mainly selling drugs (case #8). Demographic data of
all cases are presented in Table 1.
The main drug of use by the adolescents was crack
heroin while five (41.5%) reported the concurrent use of
methamphetamine and four (33.3%) reported the concur-
rent use of methamphetamine, opium, and or opium sap
(shireh). The average cost of using illicit drugs was in the
range of 12.000 to 50.000 tomans (mean ± SD: 23.19 ±
10.68). None of the study participants admitted any history
of drug injection. Only one (8.3%) youth reported regular
cigarette use during the last month. The age at the first use
of illicit drugs was between 6 and 14 years old (mean± SD:
10.17 ± 2.25). None of the cases had any previous history of
receiving addiction treatment services. Three boys (cases
#1, #3, and #5) reported a previous history of incarceration.
Among them, cases #1 and #3 had three and seven months
of detention history in juvenile correctional settings, re-
spectively. The drug use history of the cases appears in Ta-
ble 2.
All the adolescents received a medically supervised as-
sisted withdrawal with buprenorphine. The maximum
daily dose of buprenorphine was in the range of 2 to 10 mg
(mean ± SD: 7 ± 2.6 mg). The duration of buprenorphine
dosing was between 5 and 14 days (mean ± SD: 10.4 ± 2.5
mg). Figure 1 presents the average daily dose of buprenor-
phine from day 1 to day 15. All the complaints of pain and
other withdrawal signs and symptoms decreased dramat-
ically within the first four days of treatment. Seven out
of eight boys and one out of four girls were diagnosed
with pediculosis at the time of hospitalization and they re-
ceived treatment for it. Three boys (cases 1, 3, and 11) were
diagnosed with conduct disorder. One case (#6) suffered
from a current diagnosis of PTSD. After discontinuation of
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Table 1. A Summary of the Demographic Characteristics




















1 13 Male 5 Shia Street vend 8 8 Yes Yes Home Father
2 13 Male 3 Shia Street vend 0 0 Deceased Yes Home Mother
3 15 Male 5 Shia Street vend 0 0 Yes Yes Home Father
4 17 Female 7 Shia - 8 5 Yes Yes Home Mother
5 15 Male 3 Shia Salesclerk 7 0 Yes Yes Home Mother
6 12 Male 0 Sunni Street vend 0 0 Yes Yes Street Parents
7 14 Female 1 Sunni - 0 0 Yes Yes Home Parents
8 12 Male 1 Shia Begging 0 0 Yes No Home Parents
9 13 Male 0 Shia Street vend 0 0 Deceased No Home Mother
10 12 Female 3 Shia Begging 8 0 Yes Yes Home Parents
11 15 Female 5 Sunni Begging 0 0 Yes Yes Home Mother
12 13 Male 3 Shia Street vend 0 0 Deceased Yes Home Mother
Table 2. A Summary of the Substance Use History














Age of the First
Illegal Drug Use








1 CH No MA 20.000 No 12 OR 12 Theft
2 CH No MA 35.000 No 6 CH, MA 84 -
3 CH No MA 50.000 No 11 CH, MA 48 Theft
4 CH No - 15.000 No 14 CH 36 -
5 CH No MA, O, OR 15.000 No 10 OR 60 -
6 CH No MA 30.000 No 12 CH 3 -
7 CH No - 20.000 No 8 CH, MA 72 -
8 CH No MA, O, OR 12.000 No 8 OR 48 Theft
9 CH No MA 30.000 No 8 CH, MA 48 Theft
10 CH Yes MA, O, OR 20.000 No 11 CH 10 -
11 CH No - 20.000 No 11 CH 12 Theft
12 CH No MA, O 20.000 No 11 CH 48 -
Abbreviations: CH, crack heroin; MA, methamphetamine; O, opium; OR, opium residue (shireh).
the buprenorphine treatment and medical and psychiatric
stabilization, the study participants were discharged. The
length of the hospital stay was in the range of 12 to 23 days
(mean± SD: 14.66±2.9 days). While most of the cases were
discharged within two weeks, the patient with PTSD (case
#6) needed a longer duration of inpatient treatment (23
days).
All participants were transferred to the foster care after
discharge since none of their parents had eligibility of hav-
ing their guardianship. At one-month follow-up, all study
participants were still in the foster care and the urine tests
for morphine and methamphetamine were negative. At
the three-month follow-up, the older sister of the only one
15-year-old adolescent (case #3) took the responsibility of
his guardianship. The urine tests of all study participants
were negative in month 3. Table 3 presents the treatment
descriptions of all patients.
5. Discussion
This study documents the feasibility and effectiveness
of inpatient buprenorphine-assisted opioid withdrawal
among vulnerable adolescents in Iran. Although the ma-
jority of the adolescents who have substance use disor-
ders could receive treatment in outpatient settings (25),
the lack of a supportive environment for recovery and high
risk for relapse necessitated 24-hour care for all reported
cases in this study. This was in line with the international
criteria for patient placement in substance use disorder
treatment settings (26). Further studies are needed to in-
vestigate the safety and efficacy of withdrawal and main-
tenance treatment with buprenorphine in community set-
tings.
The participants in this study were in the early stages
of their adolescence with a mean age of 13.5 years. None
of the cases had a previous history of addiction treatment,
which might be due to their lack of parental support and
4 Int J High Risk Behav Addict. 2019; 8(1):e66470.
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Figure 1. The average daily dose of buprenorphine
Table 3. A Summary of the Treatment Process and Outcomes





Length of Hospital Stay
(Days)
Retention at One Month Retention at Three
Months
1 10 8 14 Yes Yes
2 12 6 14 Yes Yes
3 12 8 14 Yes Yes
4 14 10 15 Yes Yes
5 11 8 14 Yes Yes
6 10 4 23 Yes Yes
7 13 10 17 Yes Yes
8 11 6 13 Yes Yes
9 5 4 12 Yes Yes
10 9 6 13 Yes Yes
11 7 8 13 Yes Yes
12 11 6 14 Yes Yes
supervision, as well as the very low socioeconomic status
of their families. This is consistent with international stud-
ies mentioning the familial and social factors as poten-
tial barriers to treatment access (27, 28). This observation
suggests high levels of unmet need for drug treatment
among street-connected adolescents with opioid use dis-
order, which necessitates the implementation of outreach
and service linkage programs for them using standard pro-
cedures (29).
The main drug of use of all patients was crack heroin
and about two-thirds of them reported the concurrent use
of other drugs mainly methamphetamine. This drug use
profile was comparable with that of participants in a multi-
site clinical trial of buprenorphine treatment among ado-
lescents (30), but it was in contrast to the review level
data on the profile of drug use among street children in
resource-constrained countries that reported inhalants as
the most common drug of use (31). Besides, it was incon-
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sistent with the national epidemiologic data on the profile
of drug use among the 15 to 64-year-old population that
showed opium as the main drug of use in the country (1,
32), suggesting more severe and advanced illness among
the study participants.
In this study, only two patients reported a history of
sexual activities in their lives. This is inconsistent with
international studies reporting high rates of risky sexual
practices among substance-using street adolescents (33,
34). They also denied any history of injecting drug use in
their lifetime. This could be explained by the referral con-
dition of these adolescents from the criminal justice sys-
tem, as well as the willingness of the study participants to
provide socially desirable answers to treatment providers.
Addiction in parents and low social support are the
facts found in patients’ history, which are consistent with
the results of a previous meta-analysis study in the coun-
try (9). Previous studies have documented relatively high
rates of attrition and relapse to opioid use following
short-term buprenorphine-assisted withdrawal treatment
among adolescents (15, 16, 35, 36). Attrition is particularly
high among youth who do not receive psychosocial ser-
vices. Addiction and lack of social stability among par-
ents is associated with higher rates of drug treatment fail-
ure among adolescents (28, 37). All these data suggest the
high risk for relapse following short-term buprenorphine
detoxification among study participants who were street
adolescents with a low socioeconomic background. Stud-
ies among adults who were dependent on opioids indi-
cated an increased risk of the fatal overdose after discharge
from an inpatient detoxification program (38) or correc-
tional settings (39, 40). Therefore, it can be concluded
that medically managed opioid withdrawal must be con-
sidered only as a part of a comprehensive psychosocial pro-
gram providing a stable living environment, adolescent
welfare, and custody services. In our study, providing a
coordinated care by the Child and Adolescent Psychiatric
Ward, Provincial Welfare Organization, and Child Custody
Court guaranteed the abstinence of patients in a three-
month follow-up. Stress resulted from real-life challenges
would emerge after returning of the patient to the commu-
nity, which might happen through granting child custody
to a healthy family member or parents after the success-
ful completion of addiction treatment program. Further
studies with long-term follow-ups are required to investi-
gate long-term treatment needs and outcomes of vulnera-
ble adolescents with opioid use disorders.
The majority of the patients were discharged after
achieving physical and psychiatric stability within 14 days.
At the time of the study, none of the child and psychiatric
wards provided treatments for opioids use disorder with
opioid agonists in the country and this is the first study
representing preliminary data on feasibility, safety, and ef-
fectiveness of integration of agonist treatment services in
child psychiatry settings. However, it should be noted that
detoxification is an inadequate treatment for opioids use
disorder and it needs to be combined with intensive devel-
opmentally appropriate psychosocial support addressing
both the adolescents and their families (41). There are lim-
ited data that support the extended use of agonist and an-
tagonist medications for treatment of opioid use disorders
among adolescents (15-17, 42, 43) although it seems that
adolescents with a stable family environment who seek
treatment from community settings might be appropriate
candidates for extended pharmacotherapies.
Our findings suggest the feasibility of providing in-
patient buprenorphine-assisted withdrawal through inpa-
tient sub-child and adolescent psychiatric wards. The treat-
ment program also proved its safety and effectiveness for
the management of pain and other opioid withdrawal
signs and symptoms among adolescents. Our study has
several limitations including observational design, low
sample size, and only three months of follow-up.
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